Sotac Pharmaceuticals share news, announcements and annual reports

NSE: SOTACPharmaceuticals & Biotechnology

Sotac Pharmaceuticals Limited · Face value ₹10 · Listed Apr 2023 · Issue price ₹111

₹101.30₹4.80 (4.97%)

Share price at the NSE close on 28 Oct 2026. Previous close ₹96.50.

28 Oct: open ₹101.25, high ₹101.30, low ₹101.25

52-week range of traded prices to 28 Oct 2026

₹86.00Low, 31 Jul 2026₹139.65High, 28 Nov 2025

Market cap: ₹112 Cr
P/E: 19.41
P/B: 1.90
Dividend yield: 0.20%
ROE: 10.3%
Debt to equity: 0.58
Volume, NSE: 2,400100.0% delivered

Sotac Pharmaceuticals share news and announcements

103 announcements, routine notices left out, newest first. Page 2 of 3.

Aug 2024
- 13 Aug · Board meeting
  Board meeting held on August 13, 2024.
- 8 Aug · Management
  Resignation of Independent director.
- 8 Aug · Management
  Resignation of Ms Nidhiben Patel as Independent Director of the company w.e.f. August 08, 2024.
- 8 Aug · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters
Jul 2024
- 16 Jul · Updates
  'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'. In terms of Regulation 30 read with Para B of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, Sotac Pharmaceuticals Limited ( The Company ), wish to inform that Sotac Lifesciences Private Limited, subsidiary company of Sotac Pharmaceuticals Limited ( Sotac ) has entered into a Manufacturing Agreement (Loan License Contract) dated 16th July 2024 for production of agreed volume or quantities for ready-mix materials used for coating of pharmaceutical tablets ( the Products ) per year for next 10 years
- 15 Jul · Updates
  Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015.
Jun 2024
- 25 Jun · Updates
  We arepleased to inform that our Company has received Letter of Acceptance on June 11, 2024 of Approx. Rs. 17,13,01,433/-(including GST) from Rajasthan Medical Services Corporation Limited for supply of various Pharmaceuticals productsThis order presents a remarkable opportunity for our company to demonstrate our manufacturing capabilities and tostrengthen our relationship with our customers
May 2024
- 17 May · Board meeting
  Board meeting held on May 17, 2024.
- 17 May · Results
  Financial results for the period ended March 31, 2024.
- 9 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2024 and other business matters
Apr 2024
Feb 2024
- 5 Feb · Results
  Financial results for the period ended December 31, 2023.
- 5 Feb · Board meeting
  Board meeting held on February 05, 2024 for approval of financial results.
Jan 2024
- 20 Jan · Board meeting
  To consider and approve the financial results for the period ended December 31, 2023 and other business matters
- 8 Jan · Updates
  Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015.
Nov 2023
- 6 Nov · Results
  Financial results for the period ended September 30, 2023.
- 6 Nov · Board meeting
  Sub: Outcome of Board Meeting held today i.e. on November 06, 2023 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE0O2D01012)In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Monday, November 06, 2023, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, which was commenced at 4:30 P.M. and concluded at 5:55 P.M., have;1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the Half year ended on September 30, 2023, 2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Half year ended on September 30, 2023,3. Statement of Assets and Liabilities,4. Cash Flow Statement,5. Considered and approved all other business as per agenda circulated.Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the Standalone and Consolidated Unaudited Financial Results for the Half year ended September 30, 2023 and Limited Review Report issued by Statutory Auditors on the Standalone and Consolidated Unaudited Financial results for the half year ended on September 30, 2023.
Oct 2023
- 30 Oct · Board meeting
  Intimation of Board meeting for consideration of Unaudited Financial Results of the Company for the Half year ended on September 30, 2023
- 10 Oct · Updates
  Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sep 2023
- 13 Sep · Meeting
  Copy Srutinizers report of Annual General Meeting held on September 11, 2023. Further, the company has informed the Exchange regarding voting results.
- 11 Sep · Meeting
  Proceedings of Annual General Meeting held on September 11, 2023 along with a copy of minutes.
Aug 2023
- 19 Aug · Meeting
  Notice of Annual General Meeting to be held on September 11, 2023
- 11 Aug · Business
  Statement of deviation(s) or variation(s) under Reg. 32
- 11 Aug · Updates
  Appointment of M/s. Suthar Haresh & Associates, Cost Accountants, and M/s. Keyur Shah & Co., Chartered Accountants
- 11 Aug · Management
  Appointment of Ms Niyati Dipesh Parikh as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2023.
- 11 Aug · Board meeting
  Board meeting held on August 11, 2023.
- 11 Aug · Results
  Financial results for the period ended June 30, 2023.
- 5 Aug · Updates
  Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) - Intimation for Resignation of Company Secretary.
- 5 Aug · Management
  Resignation of Ms Pooja Bagrecha as Company Secretary of the company w.e.f. August 05, 2023.
- 5 Aug · Board meeting
  For consideration of Unaudited Financial Results for quarter ended on June 30, 2023 and to consider other business matters.
Jul 2023
Jun 2023
- 28 Jun · Legal
  Exchange had sought clarification from Sotac Pharmaceuticals Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
- 23 Jun · Legal
  Exchange has sought clarification from Sotac Pharmaceuticals Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2023

Sotac Pharmaceuticals share news and announcements

Aug 2024

Jul 2024

Jun 2024

May 2024

Apr 2024

Feb 2024

Jan 2024

Nov 2023

Oct 2023

Sep 2023

Aug 2023

Jul 2023

Jun 2023

May 2023